NCT04681625: SILODOSING

Evaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder

Completed NA Last updated 7 December 2023

What this trial tests

NA trial testing Pelvic floor muscle training (PFMT) with suppressive urgency technique in Benign Prostatic Hyperplasia (BPH) in 172 participants. Completed in 30 September 2022.

Timeline

11 January 2021

Primary endpoint
30 June 2022

30 September 2022

Quick facts

Lead sponsor	Comenius University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	172
Start date	11 January 2021
Primary completion	30 June 2022
Estimated completion	30 September 2022
Sites	1 location across Slovakia

Drugs / interventions tested

• Pelvic floor muscle training (PFMT) with suppressive urgency technique

Conditions studied

• Benign Prostatic Hyperplasia (BPH) — all drugs for Benign Prostatic Hyperplasia (BPH) →
• Overactive Bladder — all drugs for Overactive Bladder →

Sponsor

Comenius University

Who can join

50 and older, male only, with Benign Prostatic Hyperplasia (BPH) or Overactive Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder treated with Silodosin.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder.
   Hagovska M, Svihra J, Macko L, Breza J, et al · · 2024 · cited 4× · PMID 38698269 · DOI 10.1007/s00345-024-04974-7
2. Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant).
   Hagovska M, Svihra J. · · 2021 · PMID 34769943 · DOI 10.3390/ijerph182111426